速递｜新减重药竞争力不足，罗氏终止27亿美元收购来的一款早期肥胖药物

Core Viewpoint - Roche has decided to discontinue the development of its early obesity candidate drug CT-173 due to competitive considerations and internal standards not being met [2][3]. Group 1: Drug Development and Discontinuation - Roche's pharmaceutical department head, Teresa Graham, stated that CT-173 did not meet the expected thresholds based on the company's development potential and market competitiveness standards [3]. - The drug CT-173, acquired for $2.7 billion from Carmot Therapeutics in December 2023, is a molecule that mimics the gut hormone PYY, which regulates insulin secretion and appetite suppression when blood sugar levels rise [3]. - Despite initial positive signals from early studies showing that CT-173 combined with CT-388 could break weight loss plateau in mouse models, the decision to abandon CT-173 was made [5][6]. Group 2: Impact on Roche's Obesity Pipeline - Graham emphasized that the abandonment of CT-173 has a minimal impact on Roche's overall obesity project, noting that the molecule is still in a very early stage [6]. - The company remains confident in its obesity pipeline and plans to continue investing in promising obesity treatment products that have the potential to be industry-leading [6]. - This decision reflects Roche's strategic direction to prioritize clinical and commercial prospects of its strongest assets [7].